Molecular Pathways and Treatment Updates on Huntington’s Disease with Special Preference to Juvenile Phase: A Comprehensive Review

Title:Molecular Pathways and Treatment Updates on Huntington’s Disease with Special Preference to Juvenile Phase: A Comprehensive Review

Volume: 5 Issue: 1

Author(s): Kunal Suryavanshi, Anuj Kumar Sharma, Yogesh Murti, Vibha Kumari, Karuna Shanker Shukla and Mayank Kulshreshtha*

Affiliation:

• 1Rajiv Academy for Pharmacy, Mathura, India

Keywords: Huntington’s disease, Chorea, Antidopaminergic agents, Antipsychotic agents, Omega- 3 fatty acids, N-Methyl-D-aspartic acid receptor antagonists.

Abstract: A degenerative brain ailment called Huntington's disease (HTD) causes irritable behavior, emotional distress, cognition, etc. It is also known as Huntington's chorea. Compared to men, women are more likely to get HTD. However, in India, if 3 to 5% of Europeans are affected, it is difficult to estimate the disease's prevalence. The full pathophysiological status, several molecular pathways, and pharmaceutical and non-pharmacological treatments for Huntington's disease are covered in this article. Google, PubMed, Scopus, Bentham, Elsevier, and other significant web resources were used to gather the scientific data. Moreover, this review article may serve as the foundation for future study, particularly on Huntington's illness.

Cite this article as:

Suryavanshi Kunal, Sharma Anuj Kumar, Murti Yogesh, Kumari Vibha, Shanker Shukla Karuna and Kulshreshtha Mayank*, Molecular Pathways and Treatment Updates on Huntington’s Disease with Special Preference to Juvenile Phase: A Comprehensive Review, New Emirates Medical Journal 2024; 5 : e02506882276317 . https://dx.doi.org/10.2174/0102506882276317240111103545